Business context and reporting period
USANA Health Sciences, Inc. filed this Form 8-K on October 5, 2026, reporting a September 30, 2026 amendment to its Third Amended and Restated Credit Agreement dated June 27, 2025. The filing concerns financing terms, not quarterly operating results.
Key financial and financing terms
- Revolving credit facility: $75 million, maturing June 27, 2030. The agreement permits a potential increase on company request, but the filing’s description of the increase amount is unclear.
- Minimum Consolidated EBITDA covenant: Beginning with the fiscal quarter ending October 3, 2026, at least $100 million for each trailing four-fiscal-quarter period. The minimum falls to $70 million if aggregate Revolving Exposure is $50 million or less on the period’s last day.
- General asset-sale basket: Annual permitted aggregate book value increased from $500,000 to $2.5 million.
- Sydney property: USANA Australia Pty, Ltd may sell real property in Sydney, Australia and use net proceeds as determined in its reasonable business judgment.
- Sale-leasebacks: Generally remain prohibited, with exceptions for transactions agreed to by Required Lenders and qualifying Sydney property dispositions.
The filing does not disclose amounts drawn or outstanding under the facility, cash balances, revenue, earnings, cash flow, margins, or other operating results. It therefore does not provide a clear measure of current debt usage or liquidity beyond the facility commitment.
Material changes versus prior terms
The amendment adds the minimum EBITDA covenant, increases the general asset-sale basket, authorizes the specified Sydney property sale, and adds a related exception to the sale-leaseback restriction. Other credit-agreement and loan-document terms remain in force.
Management commentary, risks, and unusual items
The loan parties reaffirmed their obligations and liens, confirmed their representations and warranties (subject to applicable materiality qualifications), and stated that no default or event of default existed. The filing provides no business outlook or earnings guidance. The new EBITDA covenant and restrictions on asset dispositions are key financing conditions to monitor; the Sydney sale is specifically permitted, but no sale price, timing, or proceeds amount is disclosed.
Investor facts to verify
- Review Exhibit 10.1 for the precise language on the facility’s potential increase and the amended sale-leaseback definition.
- Check subsequent filings for facility borrowings, availability, and compliance with the new EBITDA covenant.
- Monitor whether the Sydney property is sold, the proceeds received, and their use.
- Confirm whether any future filing reports changes to the stated no-default position.